These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22005785)

  • 21. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.
    Germain C; Larbouret C; Cesson V; Donda A; Held W; Mach JP; Pèlegrin A; Robert B
    Clin Cancer Res; 2005 Oct; 11(20):7516-22. PubMed ID: 16243826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.
    Morgado S; Sanchez-Correa B; Casado JG; Duran E; Gayoso I; Labella F; Solana R; Tarazona R
    J Innate Immun; 2011; 3(4):365-73. PubMed ID: 21576932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
    Wittenbrink M; Spreu J; Steinle A
    Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
    Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
    Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY; Mei JZ; Yao KT
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Requirements for control of B-cell lymphoma by NK cells.
    Brenner CD; King S; Przewoznik M; Wolters I; Adam C; Bornkamm GW; Busch DH; Röcken M; Mocikat R
    Eur J Immunol; 2010 Feb; 40(2):494-504. PubMed ID: 19950185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
    López-Soto A; Folgueras AR; Seto E; Gonzalez S
    Oncogene; 2009 Jun; 28(25):2370-82. PubMed ID: 19430493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
    Poggi A; Catellani S; Garuti A; Pierri I; Gobbi M; Zocchi MR
    Leukemia; 2009 Apr; 23(4):641-8. PubMed ID: 19151770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
    Hassold N; Seystahl K; Kempf K; Urlaub D; Zekl M; Einsele H; Watzl C; Wischhusen J; Seggewiss-Bernhardt R
    Int J Cancer; 2012 Sep; 131(6):E916-27. PubMed ID: 22419518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.
    Ullrich N; Heinemann A; Nilewski E; Scheffrahn I; Klode J; Scherag A; Schadendorf D; Singer BB; Helfrich I
    Cancer Res; 2015 May; 75(9):1897-907. PubMed ID: 25744717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
    Jachimowicz RD; Fracasso G; Yazaki PJ; Power BE; Borchmann P; Engert A; Hansen HP; Reiners KS; Marie M; von Strandmann EP; Rothe A
    Mol Cancer Ther; 2011 Jun; 10(6):1036-45. PubMed ID: 21525185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Fusion Antibody Exhibits Antiangiogenic Activity and Stimulates NK Cell-mediated Immune Surveillance Through Fused NKG2D Ligand.
    Acheampong DO; Tang M; Wang Y; Zhao X; Xie W; Chen Z; Tian W; Wang M; Zhang J
    J Immunother; 2017 Apr; 40(3):94-103. PubMed ID: 28234666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
    Ding H; Yang X; Wei Y
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutting edge: NKG2D-dependent cytotoxicity is controlled by ligand distribution in the target cell membrane.
    Martinez E; Brzostowski JA; Long EO; Gross CC
    J Immunol; 2011 May; 186(10):5538-42. PubMed ID: 21464092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sesamolin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt's lymphoma cells.
    Kim JH; Lee JK
    Int Immunopharmacol; 2015 Oct; 28(2):977-84. PubMed ID: 26298637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.
    Vyas M; Koehl U; Hallek M; von Strandmann EP
    Trends Mol Med; 2014 Feb; 20(2):72-82. PubMed ID: 24268686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.